Savas Guzel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Savas Guzel has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Ahsen Yılmaz
Department of Biochemistry, Medicine Faculty Tekirdağ Namik Kemal University Tekirdag Turkey
8 shared publications - Aydın Akyüz
Namık Kemal University, Turkey
5 shared publications - Aliye Çelikkol
Tekirdağ Namık Kemal University, Faculty of Medicine
4 shared publications - Demet Ozkaramanli Gur
Namik Kemal Univ, Dept Cardiol, Fac Med, Tekirdag, Turkey
4 shared publications Eda Celik Guzel
4 shared publications- Şeref Alpsoy
Tekirdağ Namık Kemal University
4 shared publications
Latest Publications
- 18 June 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2054-2065
Interictal serum L‐kynurenine and PACAP‐38 levels in relation to allodynia and migraine subtypes
Objective: This study aimed to evaluate the relationship between serum levels of L‐kynurenine (L‐KYN) and pituitary adenylate cyclase‐activating polypeptide‐38 (PACAP‐38), two molecules implicated in migraine pathophysiology and migraine subtypes (episodic and chronic), as well as the presence of allodynia. We hypothesized that dysregulation of the kynurenine pathway and prepro‐pituitary adenylate cyclase‐activating polypeptide (PACAP) signaling would be reflected in altered serum L‐KYN and PACAP‐38 levels across migraine subtypes and in relation to allodynia. Background: Migraine is a complex neurological disorder characterized by central sensitization and trigeminovascular activation. Although the kynurenine pathway and PACAP‐38 have been implicated in migraine pathophysiology, their associations with migraine subtypes and allodynia remain insufficiently understood. Methods: In this observational cross‐sectional study, a total of 137 patients diagnosed with migraine who presented to the neurology outpatient clinic of a tertiary university hospital, and 40 age‐ and sex‐matched healthy volunteers as a control group, were included. Interictal serum L‐KYN and PACAP‐38 levels were measured in all participants using the enzyme‐linked immunosorbent assay. Clinical assessments comprised the Beck Depression Inventory, Beck Anxiety Inventory, MIDAS, Allodynia Symptom Checklist, and a visual analogue scale. Data analyses included nonparametric tests, correlation analyses, and multivariable logistic and robust regression models. Results: Interictal serum L‐KYN and PACAP‐38 levels were significantly lower in patients with migraine compared with controls (PACAP‐38: H (2) = 84.742, p < 0.001; L‐KYN: H (2) = 68.991, p < 0.001), with numerically lower levels in chronic migraine than in episodic migraine. Both molecules showed strong discriminatory ability between patients with migraine and healthy controls (area under the curve = 0.977 for PACAP‐38; area under the curve = 0.922 for L‐KYN). A strong positive correlation was observed between serum L‐KYN and PACAP‐38 levels ( ρ = 0.772, p < 0.001). Aura (odds ratio = 4.6, 95% confidence interval [1.3 to 16.2], p = 0.017) and secondary/high school educational level (odds ratio = 6.8, 95% interval [1.5 to 31.3], p = 0.015) emerged as independent predictors of allodynia. Conclusion: Interictal serum L‐KYN and PACAP‐38 levels are associated with migraine subtypes and allodynia, with potential utility as clinically relevant peripheral indicators associated with migraine‐related neurobiological processes.
- 18 June 2026
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (9) , 2054-2065
Interictal serum L‐kynurenine and PACAP‐38 levels in relation to allodynia and migraine subtypes
Objective: This study aimed to evaluate the relationship between serum levels of L‐kynurenine (L‐KYN) and pituitary adenylate cyclase‐activating polypeptide‐38 (PACAP‐38), two molecules implicated in migraine pathophysiology and migraine subtypes (episodic and chronic), as well as the presence of allodynia. We hypothesized that dysregulation of the kynurenine pathway and prepro‐pituitary adenylate cyclase‐activating polypeptide (PACAP) signaling would be reflected in altered serum L‐KYN and PACAP‐38 levels across migraine subtypes and in relation to allodynia. Background: Migraine is a complex neurological disorder characterized by central sensitization and trigeminovascular activation. Although the kynurenine pathway and PACAP‐38 have been implicated in migraine pathophysiology, their associations with migraine subtypes and allodynia remain insufficiently understood. Methods: In this observational cross‐sectional study, a total of 137 patients diagnosed with migraine who presented to the neurology outpatient clinic of a tertiary university hospital, and 40 age‐ and sex‐matched healthy volunteers as a control group, were included. Interictal serum L‐KYN and PACAP‐38 levels were measured in all participants using the enzyme‐linked immunosorbent assay. Clinical assessments comprised the Beck Depression Inventory, Beck Anxiety Inventory, MIDAS, Allodynia Symptom Checklist, and a visual analogue scale. Data analyses included nonparametric tests, correlation analyses, and multivariable logistic and robust regression models. Results: Interictal serum L‐KYN and PACAP‐38 levels were significantly lower in patients with migraine compared with controls (PACAP‐38: H (2) = 84.742, p < 0.001; L‐KYN: H (2) = 68.991, p < 0.001), with numerically lower levels in chronic migraine than in episodic migraine. Both molecules showed strong discriminatory ability between patients with migraine and healthy controls (area under the curve = 0.977 for PACAP‐38; area under the curve = 0.922 for L‐KYN). A strong positive correlation was observed between serum L‐KYN and PACAP‐38 levels ( ρ = 0.772, p < 0.001). Aura (odds ratio = 4.6, 95% confidence interval [1.3 to 16.2], p = 0.017) and secondary/high school educational level (odds ratio = 6.8, 95% interval [1.5 to 31.3], p = 0.015) emerged as independent predictors of allodynia. Conclusion: Interictal serum L‐KYN and PACAP‐38 levels are associated with migraine subtypes and allodynia, with potential utility as clinically relevant peripheral indicators associated with migraine‐related neurobiological processes.
- Open Access
- 21 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-9
Preptin, PPARγ, and NLRP3 as inflammatory biomarkers in pediatric obesity – a pilot study
Childhood obesity leads to an increased inflammatory response, which in the long term can lead to serious health problems such as metabolic syndrome, diabetes, cancer and cardiovascular disease, and may also increase the risk of obesity in adulthood. Our aim was to evaluate inflammatory markers associated with pediatric obesity in 30 healthy children (BMI between the 15th–85th percentiles) and 30 obese children (BMI > 95th percentile) and to determine the possible associations of these markers. Anthropometric measurements of the children were obtained. The serum preptin, peroxisome proliferator activated receptor gamma (PPARγ), nod-like receptor pyrin domain-containing 3 (NLRP3), and interleukin-18 (IL-18) levels of thirty children with obesity and thirty healthy children were determined using ELISA. NLPR3, preptin, and PPARγ levels were greater obese children than in healthy children (p < 0.05). We have shown that high PPARγ levels may have an inhibitory effect on the inflammatory activation of NLRP3. In our study, the changes observed in preptin, NLRP3 and PPARγ parameters were found to be closely associated with pediatric obesity. These molecules may play an important role in understanding the relationship between pediatric obesity and inflammation and may be used as biomarkers in determining obesity treatment and complications in future studies.
- 21 October 2025
- Published by Springer Nature in BMC Pediatrics
- Vol. 25 (1) , 1-9
Open AccessPreptin, PPARγ, and NLRP3 as inflammatory biomarkers in pediatric obesity – a pilot study
Childhood obesity leads to an increased inflammatory response, which in the long term can lead to serious health problems such as metabolic syndrome, diabetes, cancer and cardiovascular disease, and may also increase the risk of obesity in adulthood. Our aim was to evaluate inflammatory markers associated with pediatric obesity in 30 healthy children (BMI between the 15th–85th percentiles) and 30 obese children (BMI > 95th percentile) and to determine the possible associations of these markers. Anthropometric measurements of the children were obtained. The serum preptin, peroxisome proliferator activated receptor gamma (PPARγ), nod-like receptor pyrin domain-containing 3 (NLRP3), and interleukin-18 (IL-18) levels of thirty children with obesity and thirty healthy children were determined using ELISA. NLPR3, preptin, and PPARγ levels were greater obese children than in healthy children (p < 0.05). We have shown that high PPARγ levels may have an inhibitory effect on the inflammatory activation of NLRP3. In our study, the changes observed in preptin, NLRP3 and PPARγ parameters were found to be closely associated with pediatric obesity. These molecules may play an important role in understanding the relationship between pediatric obesity and inflammation and may be used as biomarkers in determining obesity treatment and complications in future studies.
- Open Access
- 14 July 2025
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (16) , e70079
Determination of Biotin Interference in Pediatric Obesity Related ELISA Research Kits Biotin Interference in Manual ELISA Kits
Background: Although high‐dose biotin interference in automated immunoassays is now considered, there are very few studies showing biotin interference in manually operated research kits, especially with enzyme‐linked immunosorbent assay (ELISA). The aims of our study were to determine the effects of biotin interference on various parameters, including leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, peroxisome proliferator activated receptor gamma (PPARγ), nod‐like receptor pyrin domain‐containing 3 (NLRP3) and interleukin‐18 (IL‐18), which contribute to energy homeostasis in healthy and obese children.Methods: Serum pools were prepared from healthy and obese individuals, and biotin concentrations in samples containing different amounts of biotin were measured via sandwich and competitive ELISA methods. In addition, possible biotin interactions were investigated by determining the concentrations of all the study parameters in serum pools containing different amounts of biotin.Results: We found that the biotin‐competitive, ghrelin‐competitive, KISS1‐competitive, GHSR, leptin and LEPR ELISA kits were less affected by biotin interference and the results of these assay kits were more reliable. Unexpectedly, high levels were also measured in the biotin sandwich ELISA kit, indicating that biotin interference can also occur in manually operated assay kits.Conclusions: Biotin exhibited an interference effect even in well‐functioning, qualified kits, and this negative effect was less common in competitive kits. Biotin interference was closely associated with the quality of the research kit, the parameters studied, and the presence of high biotin concentrations in the blood.
- 14 July 2025
- Published by Wiley in Journal of Clinical Laboratory Analysis
- Vol. 39 (16) , e70079
Open AccessDetermination of Biotin Interference in Pediatric Obesity Related ELISA Research Kits Biotin Interference in Manual ELISA Kits
Background: Although high‐dose biotin interference in automated immunoassays is now considered, there are very few studies showing biotin interference in manually operated research kits, especially with enzyme‐linked immunosorbent assay (ELISA). The aims of our study were to determine the effects of biotin interference on various parameters, including leptin, leptin receptor (LEPR), ghrelin, acylated ghrelin, deacylated ghrelin, ghrelin receptor (GHSR), kisspeptin (KISS1), kisspeptin receptor (KISS1R), preptin, peroxisome proliferator activated receptor gamma (PPARγ), nod‐like receptor pyrin domain‐containing 3 (NLRP3) and interleukin‐18 (IL‐18), which contribute to energy homeostasis in healthy and obese children.Methods: Serum pools were prepared from healthy and obese individuals, and biotin concentrations in samples containing different amounts of biotin were measured via sandwich and competitive ELISA methods. In addition, possible biotin interactions were investigated by determining the concentrations of all the study parameters in serum pools containing different amounts of biotin.Results: We found that the biotin‐competitive, ghrelin‐competitive, KISS1‐competitive, GHSR, leptin and LEPR ELISA kits were less affected by biotin interference and the results of these assay kits were more reliable. Unexpectedly, high levels were also measured in the biotin sandwich ELISA kit, indicating that biotin interference can also occur in manually operated assay kits.Conclusions: Biotin exhibited an interference effect even in well‐functioning, qualified kits, and this negative effect was less common in competitive kits. Biotin interference was closely associated with the quality of the research kit, the parameters studied, and the presence of high biotin concentrations in the blood.
- Open Access
- 1 February 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (2) , 246-251
Cardiovascular disease risk prediction in scleroderma
OBJECTIVE: Cardiovascular disease risk prediction in scleroderma is important. In this study of scleroderma patients, the aim was to investigate the relationship between cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide and cardiovascular disease risk with the Systematic COronary Risk Evaluation 2 model of the European Society of Cardiology.METHODS: Systematic COronary Risk Evaluation 2 risk groups of 38 healthy controls and 52 women with scleroderma were evaluated. Cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide levels were analyzed with commercial ELISA kits.RESULTS: In scleroderma patients, cardiac myosin-binding protein-C and trimethylamine N-oxide levels were higher than healthy controls but sensitive troponin T was not (p<0.001, p= 10.28 ng/mL) could predict high -moderate-Systematic COronary Risk Evaluation 2 risk 15 times higher than those with low trimethylamine N-oxide (<10.28 ng/mL) levels (odds ratio [OR]: 15.00, 95%CI 3.585-62.765, p= 8.29 ng/mL) levels could predict significantly higher Systematic COronary Risk Evaluation 2 risk than low cardiac myosin-binding protein-C (<8.29 ng/mL) levels (OR: 11.00, 95%CI 2.786-43.430).CONCLUSION: Noninvasive cardiovascular disease risk prediction indicators in scleroderma, cardiac myosin-binding protein-C, and trimethylamine N-oxide could be recommended to distinguish between high-moderate risk and low risk with the Systematic COronary Risk Evaluation 2 model.
- 1 February 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (2) , 246-251
Open AccessCardiovascular disease risk prediction in scleroderma
OBJECTIVE: Cardiovascular disease risk prediction in scleroderma is important. In this study of scleroderma patients, the aim was to investigate the relationship between cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide and cardiovascular disease risk with the Systematic COronary Risk Evaluation 2 model of the European Society of Cardiology.METHODS: Systematic COronary Risk Evaluation 2 risk groups of 38 healthy controls and 52 women with scleroderma were evaluated. Cardiac myosin-binding protein-C, sensitive troponin T, and trimethylamine N-oxide levels were analyzed with commercial ELISA kits.RESULTS: In scleroderma patients, cardiac myosin-binding protein-C and trimethylamine N-oxide levels were higher than healthy controls but sensitive troponin T was not (p<0.001, p= 10.28 ng/mL) could predict high -moderate-Systematic COronary Risk Evaluation 2 risk 15 times higher than those with low trimethylamine N-oxide (<10.28 ng/mL) levels (odds ratio [OR]: 15.00, 95%CI 3.585-62.765, p= 8.29 ng/mL) levels could predict significantly higher Systematic COronary Risk Evaluation 2 risk than low cardiac myosin-binding protein-C (<8.29 ng/mL) levels (OR: 11.00, 95%CI 2.786-43.430).CONCLUSION: Noninvasive cardiovascular disease risk prediction indicators in scleroderma, cardiac myosin-binding protein-C, and trimethylamine N-oxide could be recommended to distinguish between high-moderate risk and low risk with the Systematic COronary Risk Evaluation 2 model.
- Open Access
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (4) , e20221254
Serum chromogranin A levels are associated with the SYNTAX score in coronary artery disease
In this article, we investigated the association of chromogranin A with coronary artery disease. Biochemical parameters and chromogranin A levels obtained from peripheral blood samples during coronary angiography were analyzed in 90 patients. Patients were classified into two groups, namely, SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1 (n=45) and SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (n=45). This is a cross-sectional, prospective study. Serum chromogranin A levels were significantly higher in the group with SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1 compared to the group with SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (1381.5±418.9 ng/mL and 1121.2±290.7 ng/mL, respectively; p=0.002). Serum chromogranin A levels were correlated with SYNergy between PCI with TAXUS and Cardiac Surgery score (r=0.556, p<0.04). ROC analysis showed that the area under the curve for serum chromogranin A levels was 0.687 (p=0.007), and the best cutoff value of 1,131 ng/mL had a sensitivity of 67% and a specificity of 65% for the prediction of coronary artery disease. Serum chromogranin A levels were increased in coronary artery disease patients with SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1. Increasing serum chromogranin A levels are proportional to the SYNergy between PCI with TAXUS and Cardiac Surgery score.
- 1 January 2023
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 69 (4) , e20221254
Open AccessSerum chromogranin A levels are associated with the SYNTAX score in coronary artery disease
In this article, we investigated the association of chromogranin A with coronary artery disease. Biochemical parameters and chromogranin A levels obtained from peripheral blood samples during coronary angiography were analyzed in 90 patients. Patients were classified into two groups, namely, SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1 (n=45) and SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (n=45). This is a cross-sectional, prospective study. Serum chromogranin A levels were significantly higher in the group with SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1 compared to the group with SYNergy between PCI with TAXUS and Cardiac Surgery score=0 (1381.5±418.9 ng/mL and 1121.2±290.7 ng/mL, respectively; p=0.002). Serum chromogranin A levels were correlated with SYNergy between PCI with TAXUS and Cardiac Surgery score (r=0.556, p<0.04). ROC analysis showed that the area under the curve for serum chromogranin A levels was 0.687 (p=0.007), and the best cutoff value of 1,131 ng/mL had a sensitivity of 67% and a specificity of 65% for the prediction of coronary artery disease. Serum chromogranin A levels were increased in coronary artery disease patients with SYNergy between PCI with TAXUS and Cardiac Surgery score ≥1. Increasing serum chromogranin A levels are proportional to the SYNergy between PCI with TAXUS and Cardiac Surgery score.
- 26 December 2022
- Published by Bandirma Onyedi Eylul Universitesi Saglik Bilimleri ve Arastirmalari Dergisi in Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi
- Vol. 4 (3) , 242-252
Associations of Nutritional Status, Oxidative Parameters, and Quality of Life of Breast Cancer Patients Before, During, and After Chemotherapy
Aim: We aimed to assess the associations between nutritional status, oxidative parameters, and quality of life before, during, and after chemotherapy (CT) in breast cancer patients. Material and Method: Clinical, anthropometric, demographic, quality of life, blood oxidative marker level, and dietary intake data of breast cancer patients who planned to CT were recorded. All collected data were compared between pre-CT, mid-CT, and post-CT time points. Results: Fifty women who were diagnosed with breast cancer and would start CT treatment were included in the study. Post-CT body weight and body mass index were significantly lower than the pre-CT values (p˂0.001). They both turned back to pre-CT levels at the end of CT with a decrease in total daily caloric and macronutrient intake. Consumption of specific food groups significantly decreased compared to their pre-CT consumption levels (p˂0.001). Blood oxidative stress marker analysis revealed a significant reduction in glutathione peroxidase levels with CT (p=0.007). Analysis of the quality-of-life scores revealed that post-CT scores were significantly higher than the pre-CT scores while the life quality was lowest in the mid-CT period. Conclusion: Adequate energy intake and antioxidant intake should be recommended to these patients during CT via dietary counseling to maintain healthy anthropometric measures, oxidative hemostasis, and quality of life.
- 26 December 2022
- Published by Bandirma Onyedi Eylul Universitesi Saglik Bilimleri ve Arastirmalari Dergisi in Bandırma Onyedi Eylül Üniversitesi Sağlık Bilimleri ve Araştırmaları Dergisi
- Vol. 4 (3) , 242-252
Associations of Nutritional Status, Oxidative Parameters, and Quality of Life of Breast Cancer Patients Before, During, and After Chemotherapy
Aim: We aimed to assess the associations between nutritional status, oxidative parameters, and quality of life before, during, and after chemotherapy (CT) in breast cancer patients. Material and Method: Clinical, anthropometric, demographic, quality of life, blood oxidative marker level, and dietary intake data of breast cancer patients who planned to CT were recorded. All collected data were compared between pre-CT, mid-CT, and post-CT time points. Results: Fifty women who were diagnosed with breast cancer and would start CT treatment were included in the study. Post-CT body weight and body mass index were significantly lower than the pre-CT values (p˂0.001). They both turned back to pre-CT levels at the end of CT with a decrease in total daily caloric and macronutrient intake. Consumption of specific food groups significantly decreased compared to their pre-CT consumption levels (p˂0.001). Blood oxidative stress marker analysis revealed a significant reduction in glutathione peroxidase levels with CT (p=0.007). Analysis of the quality-of-life scores revealed that post-CT scores were significantly higher than the pre-CT scores while the life quality was lowest in the mid-CT period. Conclusion: Adequate energy intake and antioxidant intake should be recommended to these patients during CT via dietary counseling to maintain healthy anthropometric measures, oxidative hemostasis, and quality of life.
- 20 October 2022
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (3) , 526-532
Investigation of Serum Folate-Receptor-1 Levels in Patients with Non-Small Cell Lung Cancer
Objective: Histopathological overexpression of folate receptor-1 (FOLR1) involved in folate transport in cell growth has been reported in various cancers. Increased serum FOLR1(sFOLR1) has also been reported in epithelial ovarian cancer. The aim was to investigate sFOLR1 levels in non-small cell lung cancer (NSCLC) patients and the response prediction of the standard chemotherapy targeting folic acid metabolism. Method: In this prospective study, sFOLR1 levels were investigated in 30 healthy individuals and 60 patients with stage4 malign metastatic NSCLC before and after standard chemotherapy. The commercial immunoassay (ELISA) kit used for analysis of sFOLR1. Serum carcinoembryonic antigen (CEA), vitamin B12, and folate levels were also investigated. Result: In NSCLC patients sFOLR1 levels were significantly higher(p<0.001) than the healthy individuals. After 3 months of standard treatment, sFOLR1 was significantly lower in patients(p<0.001). Diagnostic accuracy was strong in the differentiation of NSCLC patients from healthy individuals (AUC= 0.966). with the cut-off point of 82.45 pg/ml, the sFOLR1 level was performed with 95% sensitivity and 99% specificity. Pretreatment sFOLR1 levels were significantly lower in patients with-response to standard chemotherapy(p<0.01). The best predictive value was determined as 393.80 pg/ml. At the end of the 401 days, a significant difference found in patients with high the sFOLR1 predictive value. The median overall survival (OS) duration was 288 days for all patients (95% GA 198.13-377.87). Median progression-free survival (PFS) was 321 days (95% GA 211.90-430.10). Conclusion: For monitoring standard chemotherapy with drugs targeting folic acid metabolism, sFOLR-1 levels may be important biomarker.
- 20 October 2022
- Published by Konuralp Medical Journal in Konuralp Tip Dergisi
- Vol. 14 (3) , 526-532
Investigation of Serum Folate-Receptor-1 Levels in Patients with Non-Small Cell Lung Cancer
Objective: Histopathological overexpression of folate receptor-1 (FOLR1) involved in folate transport in cell growth has been reported in various cancers. Increased serum FOLR1(sFOLR1) has also been reported in epithelial ovarian cancer. The aim was to investigate sFOLR1 levels in non-small cell lung cancer (NSCLC) patients and the response prediction of the standard chemotherapy targeting folic acid metabolism. Method: In this prospective study, sFOLR1 levels were investigated in 30 healthy individuals and 60 patients with stage4 malign metastatic NSCLC before and after standard chemotherapy. The commercial immunoassay (ELISA) kit used for analysis of sFOLR1. Serum carcinoembryonic antigen (CEA), vitamin B12, and folate levels were also investigated. Result: In NSCLC patients sFOLR1 levels were significantly higher(p<0.001) than the healthy individuals. After 3 months of standard treatment, sFOLR1 was significantly lower in patients(p<0.001). Diagnostic accuracy was strong in the differentiation of NSCLC patients from healthy individuals (AUC= 0.966). with the cut-off point of 82.45 pg/ml, the sFOLR1 level was performed with 95% sensitivity and 99% specificity. Pretreatment sFOLR1 levels were significantly lower in patients with-response to standard chemotherapy(p<0.01). The best predictive value was determined as 393.80 pg/ml. At the end of the 401 days, a significant difference found in patients with high the sFOLR1 predictive value. The median overall survival (OS) duration was 288 days for all patients (95% GA 198.13-377.87). Median progression-free survival (PFS) was 321 days (95% GA 211.90-430.10). Conclusion: For monitoring standard chemotherapy with drugs targeting folic acid metabolism, sFOLR-1 levels may be important biomarker.
- Open Access
- 3 March 2022
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 14 (1) , 69-75
Serum Neudesin Levels in Obese Adolescents
Advances in knowledge of neurotrophic factors are now revealing the complex control of energy homeostasis and appetite, as well as the crucial role these factors play in nervous system function. The aim of this study was to assess serum levels of neudesin in adolescents with obesity and to examine the relationship between these levels and metabolic outcomes. Adolescents, aged 10-17 years were enrolled. Subjects were divided into normal weight, obese and morbidly obese subgroups. Serum neudesin concentrations were compared between the groups. In total, 88 adolescents were recruited, of whom 30 (34.1%) were normal weight, 15 (17.0%) were obese and 43 (48.9%) were morbidly obese. Neudesin levels were significantly lower in obese adolescents than in the control group (p=0.013). A correlation analysis applied to the whole study group revealed a negative correlation between serum neudesin concentration and body mass index (BMI) z scores (r=-0.40, p<0.001). Serum neudesin levels tended to increase in adolescents with metabolic syndrome, insulin resistance, dyslipidaemia, and hypertension but the differences were not significant (p=0.259, p=0.246, p=0.259, and p=0.523, respectively). Serum neudesin levels were significantly correlated with BMI z score in obese adolescents. Generally, serum neudesin levels were low in obese and morbidly obese adolescents and tended to increase with the appearance of metabolic disorders. Both obesity and associated metabolic disorders have multifactorial causes. Therefore, we suggest that the role of the neudesin molecule in the regulatory mechanisms of obesity and metabolic disorders should be further investigated with well-designed studies enrolling larger groups.
- 3 March 2022
- Published by Galenos Yayinevi in Journal of Clinical Research in Pediatric Endocrinology
- Vol. 14 (1) , 69-75
Open AccessSerum Neudesin Levels in Obese Adolescents
Advances in knowledge of neurotrophic factors are now revealing the complex control of energy homeostasis and appetite, as well as the crucial role these factors play in nervous system function. The aim of this study was to assess serum levels of neudesin in adolescents with obesity and to examine the relationship between these levels and metabolic outcomes. Adolescents, aged 10-17 years were enrolled. Subjects were divided into normal weight, obese and morbidly obese subgroups. Serum neudesin concentrations were compared between the groups. In total, 88 adolescents were recruited, of whom 30 (34.1%) were normal weight, 15 (17.0%) were obese and 43 (48.9%) were morbidly obese. Neudesin levels were significantly lower in obese adolescents than in the control group (p=0.013). A correlation analysis applied to the whole study group revealed a negative correlation between serum neudesin concentration and body mass index (BMI) z scores (r=-0.40, p<0.001). Serum neudesin levels tended to increase in adolescents with metabolic syndrome, insulin resistance, dyslipidaemia, and hypertension but the differences were not significant (p=0.259, p=0.246, p=0.259, and p=0.523, respectively). Serum neudesin levels were significantly correlated with BMI z score in obese adolescents. Generally, serum neudesin levels were low in obese and morbidly obese adolescents and tended to increase with the appearance of metabolic disorders. Both obesity and associated metabolic disorders have multifactorial causes. Therefore, we suggest that the role of the neudesin molecule in the regulatory mechanisms of obesity and metabolic disorders should be further investigated with well-designed studies enrolling larger groups.
- Open Access
- 21 January 2022
- Published by Hindawi Limited in International Journal of Hypertension
- Vol. 2022, 1-7
Serum Calprotectin Level as an Inflammatory Marker in Newly Diagnosed Hypertensive Patients
Background. Hypertension is one of the leading causes of cardiovascular mortality. Although the pathogenetic process involved is not yet fully understood, the disease involves endothelial damage and inflammation. Calprotectin is an inflammatory marker that rises in parallel with disease activity in conditions such as systemic inflammatory diseases, infection, and atherosclerosis. The purpose of this study was to evaluate inflammation through serum calprotectin levels in newly diagnosed primary hypertension patients. Methods. Forty-nine newly diagnosed hypertensive patients and 38 healthy adults were included in the study. Patients’ office blood pressure values, biochemical findings, and demographic characteristics were recorded. Serum calprotectin levels were measured using ELISA. Parameters affecting serum calprotectin levels and determinants of hypertension were evaluated. Results. Serum calprotectin levels were 242.8 (72.4–524) ng/mL in the control group and 112.6 (67.4–389.8) ng/mL in the hypertensive patient group, the difference being statistically significant ( ). There was no correlation between serum calprotectin levels and other parameters (blood pressure values, age, gender, serum creatinine, uric acid, and calcium levels) in the hypertensive group. A lower serum calprotectin level was found to be independently related to hypertension (β = −0.009, ). Serum calprotectin at a cutoff level of 128.6 ng/mL differentiated hypertensives from healthy controls with a sensitivity of 69.4% and specificity of 68.4% (AUC = 0.767). Conclusions. The results of this study were the opposite of our hypothesis that a higher calprotectin level may reflect subclinical endothelial damage in newly diagnosed hypertensive patients. Further comparative studies involving patients at different stages of hypertension may contribute to clarifying the relationship between calprotectin and hypertension. We conclude that molecular studies seem essential for understanding the place of calprotectin in hypertension-associated inflammation, a complex process.
- 21 January 2022
- Published by Hindawi Limited in International Journal of Hypertension
- Vol. 2022, 1-7
Open AccessSerum Calprotectin Level as an Inflammatory Marker in Newly Diagnosed Hypertensive Patients
Background. Hypertension is one of the leading causes of cardiovascular mortality. Although the pathogenetic process involved is not yet fully understood, the disease involves endothelial damage and inflammation. Calprotectin is an inflammatory marker that rises in parallel with disease activity in conditions such as systemic inflammatory diseases, infection, and atherosclerosis. The purpose of this study was to evaluate inflammation through serum calprotectin levels in newly diagnosed primary hypertension patients. Methods. Forty-nine newly diagnosed hypertensive patients and 38 healthy adults were included in the study. Patients’ office blood pressure values, biochemical findings, and demographic characteristics were recorded. Serum calprotectin levels were measured using ELISA. Parameters affecting serum calprotectin levels and determinants of hypertension were evaluated. Results. Serum calprotectin levels were 242.8 (72.4–524) ng/mL in the control group and 112.6 (67.4–389.8) ng/mL in the hypertensive patient group, the difference being statistically significant ( ). There was no correlation between serum calprotectin levels and other parameters (blood pressure values, age, gender, serum creatinine, uric acid, and calcium levels) in the hypertensive group. A lower serum calprotectin level was found to be independently related to hypertension (β = −0.009, ). Serum calprotectin at a cutoff level of 128.6 ng/mL differentiated hypertensives from healthy controls with a sensitivity of 69.4% and specificity of 68.4% (AUC = 0.767). Conclusions. The results of this study were the opposite of our hypothesis that a higher calprotectin level may reflect subclinical endothelial damage in newly diagnosed hypertensive patients. Further comparative studies involving patients at different stages of hypertension may contribute to clarifying the relationship between calprotectin and hypertension. We conclude that molecular studies seem essential for understanding the place of calprotectin in hypertension-associated inflammation, a complex process.
- Open Access
- 1 January 2021
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 8 (6) , 607-614
Association of lower serum irisin levels with diabetes mellitus: Irrespective of coronary collateral circulation, and syntax score
OBJECTIVE: Irisin is a myokine thought to be involved in the pathophysiological process of atherosclerosis with its' cardiovascular protective effects. Patients with diabetes mellitus (DM) have lower levels of irisin. Therefore, we investigated whether there is a connection between irisin, DM, coronary collateral circulation (CCC), and SYNTAX scores representing coronary artery disease (CAD) severity. METHODS: This study evaluated 86 patients who have at least one epicardial coronary artery with chronic total occlusion. We included Rentrop 0-1 into the poor CCC group (n=45) and Rentrop 2-3 into the good CCC group (n=41) and measured serum irisin levels. RESULTS: Irisin levels did not differ (17585 [882-37741] pg/ml and (17504 [813-47683] pg/ml, p=0.772) between the two groups. Irisin levels were lower in patients with diabetes (n=41; 14485 [813-29398] pg/ml) than those without diabetes (n=45; 19724 [865-47683] pg/ml (p=0.002). Irisin was not correlated with SYNTAX scores. In multivariate analysis, DM (OR=0.463; CI: 0.184-0.783; p=0.012) was a negative predictor of good CCC development CONCLUSION: Although its level is decreased in patients with diabetes, serum irisin levels have no role in the pathophysiology of collateral development and CAD severity.
- 1 January 2021
- Published by Kare Publishing in Northern Clinics of Istanbul
- Vol. 8 (6) , 607-614
Open AccessAssociation of lower serum irisin levels with diabetes mellitus: Irrespective of coronary collateral circulation, and syntax score
OBJECTIVE: Irisin is a myokine thought to be involved in the pathophysiological process of atherosclerosis with its' cardiovascular protective effects. Patients with diabetes mellitus (DM) have lower levels of irisin. Therefore, we investigated whether there is a connection between irisin, DM, coronary collateral circulation (CCC), and SYNTAX scores representing coronary artery disease (CAD) severity. METHODS: This study evaluated 86 patients who have at least one epicardial coronary artery with chronic total occlusion. We included Rentrop 0-1 into the poor CCC group (n=45) and Rentrop 2-3 into the good CCC group (n=41) and measured serum irisin levels. RESULTS: Irisin levels did not differ (17585 [882-37741] pg/ml and (17504 [813-47683] pg/ml, p=0.772) between the two groups. Irisin levels were lower in patients with diabetes (n=41; 14485 [813-29398] pg/ml) than those without diabetes (n=45; 19724 [865-47683] pg/ml (p=0.002). Irisin was not correlated with SYNTAX scores. In multivariate analysis, DM (OR=0.463; CI: 0.184-0.783; p=0.012) was a negative predictor of good CCC development CONCLUSION: Although its level is decreased in patients with diabetes, serum irisin levels have no role in the pathophysiology of collateral development and CAD severity.